66552 Federal Register / Vol. 60, No. 246 / Friday, December 22, 1995 / Notices

Control Act (12 U.S.C. 1817(j)) and §

225.41 of the Board’s Regulation Y (12

CFR 225.41) to acquire a bank or bank

holding company. The factors that are

considered in acting on notices are set

forth in paragraph 7 of the Act (12

U.S.C. 1817(j)(7)).

The notice is available for immediate

inspection at the Federal Reserve Bank

indicated. Once the notice has been

accepted for processing, it will also be

available for inspection at the offices of

the Board of Governors. Interested

persons may express their views in

writing to the Reserve Bank indicated

for the notice or to the offices of the

Board of Governors. Comments must be

received not later than January 10, 1996.

A. Federal Reserve Bank of Dallas

(Genie D. Short, Vice President) 2200

North Pearl Street, Dallas, Texas 75201-

2272:

1. John Smithhisler, Las Cruces, New

Mexico; to acquire an additional 2.2

percent, for a total of 11.8 percent of the

voting shares of Las Cruces B.R.G., Inc.,

Las Cruces, New Mexico, and thereby

indirectly acquire Bank of the Rio

Grande, N.A., Las Cruces, New Mexico.

Board of Governors of the Federal Reserve

System, December 18, 1995.

Jennifer J. Johnson,

Deputy Secretary of the Board.

[FR Doc. 95–31150 Filed 12–21–95; 8:45 am]

BILLING CODE 6210–01–F

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Administration of Children and

Families

Agency Information Collection Under

OMB Review

Title: National Study of Outcomes for

Children Placed in Foster Care with

Relatives.

OMB No.: New.

Description: This is a series of

interview forms for use with state

administrators, case workers, and foster

parents in seven states selected for the

study. State administrators are the Chief

Child Welfare Administrator, the fiscal

administrator, and management

information system specialist in each

state. The National Study of Outcomes

for Children Placed in Foster Care with

Relatives will be used to describe

policies, practices and characteristics

regarding placement of children in

foster care with relatives; to describe

outcomes of children placed in foster

care with relatives compared to children

placed in non-relative foster care; and to

examine the associated costs of relative

foster care compared to non-relative

foster care.

Under a contract from the

Administration on Children, Youth and

Families (ACYF), researchers from

TransAmerica Systems, Inc., will

conduct the National Study of

Outcomes for Children Placed in Foster

Care with Relatives. The study is in

three phases. Phase I was an initial onsite survey of nine States which make

extensive use of relative roster care,

which have sufficient and accessible

data, and which are willing to

participate in the survey. During Phase

II, a national study was designed based

on results from the nine State survey,

with the assistance of a Technical

Advisory Panel, consisting of nationally

recognized foster care experts; a

thorough literature review; and input

from organizations with interest in

foster children, a national study is

designed during Phase II. Phase III will

be conducting the national study,

analyzing the data, and preparing a final

report. This will include in-depth site

visits to seven States, purposively

sampled from the 34 States that are able

to identify whether children are placed

with relatives or with non-relatives.

State child welfare administrators and

workers and foster parents will be

selected for in-depth interviews.

Additionally, the research team will

also extract information form case

records and gather demographic data

and fiscal information from the States

visited.

Respondents: 441 (280 foster parents;

161 staff).

Title Number of

respondents

Number of

responses

per respondent

Average

burden per

response

Burden

hours

Administrator Interview ..................................................................................................... 7 1 2 14

Caseworker Interview ....................................................................................................... 140 1 1 140

Foster Parent Interview .................................................................................................... 280 1 1 280

Demographic Information Report ..................................................................................... 7 1 1 7

Fiscal Information Report ................................................................................................. 7 1 1 7

Total ....................................................................................................................... 441 .................... .................... 448

Estimated Total Annual Burden

Hours: 448.

Additional Information: Copies of the

proposed collection may be obtained by

writing to: Reports Clearance Officer,

Administration for Children and

Families, Department of Health and

Human Services, 370 L’Enfant

Promenade, S.W., Washington, D.C.

20447.

OMB Comment: Consideration will be

given to comments and suggestions

received within 30 days of publication.

Written comments and

recommendations for the proposed

information collection should be sent

directly to the following: Office of

Management and Budget, Paperwork

Reduction Project, 725 17th Street,

N.W., Washington, D.C. 20503, Attn:

Ms. Wendy Taylor.

Dated: December 14, 1995.

Arnold Jacobson,

Acting ACT Reports Clearance Officer.

[FR Doc. 95–31184 Filed 12–21–95; 8:45 am]

BILLING CODE 4148–01–M

Centers for Disease Control and

Prevention

Citizens Advisory Committee on Public

Health Service Activities and Research

at Department of Energy (DOE) Sites,

Savannah River Site Health Effects

Subcommittee; Meeting

In accordance with section 10(a)(2) of

the Federal Advisory Committee Act

(Pub. L. 92–463), the Agency for Toxic

Substances and Disease Registry

(ATSDR) and the Centers for Disease

Control and Prevention (CDC) announce

the following meeting.

Name: Citizens Advisory Committee on

Public Health Service Activities and
Federal Register / Vol. 60, No. 246 / Friday, December 22, 1995 / Notices 66553

Research at DOE Sites: Savannah River Site

Health Effect Subcommittee (SRS).

Times and Dates: 9 a.m.–5 p.m., January

11, 1996; 9 a.m.–12 noon, January 12, 1996.

Place: Hilton—The De Soto, 15 East Liberty

Street, Savannah, Georgia 31401, telephone

912/232–9000, FAX 912/232–6018.

Status: Open to the public, limited only by

the space available. The meeting room

accommodates approximately 75 people.

Background: Under a Memorandum of

Understanding (MOU) signed in December

1990 with DOE, the Department of Health

and Human Services (HHS) has been given

the responsibility and resources for

conducting analytic epidemiologic

investigations of residents of communities in

the vicinity of DOE facilities, workers at DOE

facilities, and other persons potentially

exposed to radiation or to potential hazards

from non-nuclear energy production use.

HHS delegated program responsibility to

CDC.

In addition, an MOU was signed in October

1990 and renewed in November 1992

between ATSDR and DOE. The MOU

delineates the responsibilities and

procedures for ATSDR’s public health

activities at DOE sites required under

sections 104, 105, 107, and 120 of the

Comprehensive Environmental Response,

Compensation, and Liability Act (CERCLA or

‘‘Superfund’’). These activities include health

consultations and public health assessments

at DOE sites listed on, or proposed for, the

Superfund National Priorities List and at

sites that are the subject of petitions from the

public; and other health-related activities

such as epidemiologic studies, health

surveillance, exposure and disease registries,

health education, substance-specific applied

research, emergency response, and

preparation of toxicological profiles.

Purpose: This Subcommittee is charged

with providing advice and recommendations

to the Director, CDC and the Administrator,

ATSDR, regarding community American

Indian Tribes, and labor concerns pertaining

to CDC’s and ATSDR’s public health

activities and research at respective DOE

sites. Activities shall focus on providing a

forum for community, American Indian

Tribal, and labor interaction and serve as a

vehicle for community concern to be

expressed as advice and recommendations to

CDC and ATSDR.

Matters to be Discussed: This

Subcommittee will listen to presentations

from the Radiological Assessments

Corporation, Medical University of South

Carolina Cancer Registry, as well as updates

on the Savannah River Site Phase II Dose

Reconstruction Project findings and

implications. Additional agenda items will

include: the National Center for

Environmental Health (NCEH) activities, the

National Institute for Occupational Safety

and Health and ATSDR presentations on the

progress of current studies, and issues

regarding the Committee selection process.

Agenda items are subject to change as

priorities dictate.

Contact Persons for More Information: Paul

G. Renard or Nadine Dickerson, Radiation

Studies Branch, Division of Environmental

Hazards and Health Effects, NCEH, CDC,

4770 Buford Highway, NE, (F–35), Atlanta,

Georgia 30341–3724, telephone 770/488–

7040, FAX 770/488–7044.

Dated: December 18, 1995.

Carolyn J. Russell,

Director, Management Analysis and Services

Office, Centers for Disease Control and

Prevention.

[FR Doc. 95–31152 Filed 12–21–95; 8:45 am]

BILLING CODE 4163–18–M

Food and Drug Administration

Grassroots Regulatory Partnership

Meeting; Southwest Region; Importing

Commodities

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice of a public meeting.

SUMMARY: The Food and Drug

Administration (FDA) (Office of

Regulatory Affairs, Office of the

Southwest Region, and Office of

External Affairs) is announcing a free

public meeting to discuss ways FDA

could regulate imported commodities

more efficiently, improve levels of

communication with industries and

individuals associated with the

importation of FDA-regulated

commodities, and provide improved

levels of consumer protection in

connection with imported commodities

being shipped into the United States

across the United States-Mexico border.

This meeting is intended to identify and

evaluate opportunities for implementing

the President’s initiative for a

partnership approach between the

agency and the people affected by the

work of this agency.

DATES: The public meeting will be held

on Wednesday, January 31, 1996, from

9 a.m. to 12 m.

ADDRESSES: The public meeting will be

held at the Concourse Clarion Hotel,

Oxford Room A and B, 6789 Boeing, El

Paso, TX 79926.

FOR FURTHER INFORMATION CONTACT:

Barbara A. Cain, Food and Drug

Administration, 300 East Eight St., rm.

B123, Austin, TX 78701, 512–482–5736,

or Robert G. Rast, Food and Drug

Administration, 9777 Via De La

Amistad, rm. 128, San Diego, CA 92173,

619–661–3273.

SUPPLEMENTARY INFORMATION: There is

no registration fee for this meeting.

However, due to space limitations, early

registration is recommended. This

meeting is intended to assist importers,

brokers, and others associated with a

wide variety of products being shipped

through the southwest and west coast

(FDA Southwest and Pacific Regions).

Dated: December 15, 1995.

William K. Hubbard,

Associate Commissioner for Policy

Coordination.

[FR Doc. 95–31195 Filed 12–21–95; 8:45 am]

BILLING CODE 4160–01–F

[Docket No. 95N–0403]

Drug Export; SURGISCREEN 0.8

Percent, Reagent Red Blood Cells

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

SUMMARY: The Food and Drug

Administration (FDA) is announcing

that Ortho Diagnostic Systems, Inc., has

filed an application requesting approval

for the export of the human biological

product SURGISCREEN 0.8 percent,

Reagent Red Blood Cells to Australia,

Austria, Belgium, Canada, Denmark,

The Federal Republic of Germany,

Finland, France, Iceland, Ireland, Italy,

Japan, Luxembourg, The Netherlands,

New Zealand, Norway, Portugal, Spain,

Sweden, Switzerland, and The United

Kingdom.

ADDRESSES: Relevant information on

this application may be directed to the

Dockets Management Branch (HFA–

305), Food and Drug Administration,

12420 Parklawn Dr., rm. 1–23,

Rockville, MD 20857, and to the contact

person identified below. Any future

inquiries concerning the export of

human biological products under the

Drug Export Amendments Act of 1986

should also be directed to the contact

person.

FOR FURTHER INFORMATION CONTACT:

Cathy E. Conn, Center for Biologics

Evaluation and Research (HFM–610),

Food and Drug Administration, 1401

Rockville Pike,Rockville, MD 20852–

1448, 301–594–2006.

SUPPLEMENTARY INFORMATION: The drug

export provisions in section 802 of the

Federal Food, Drug, and Cosmetic Act

(the act) (21 U.S.C. 382) provide that

FDA may approve applications for the

export of human biological products

that are not currently approved in the

United States. Section 802(b)(3)(B) of

the act sets forth the requirements that

must be met in an application for

approval. Section 802(b)(3)(C) of the act

requires that the agency review the

application within 30 days of its filing

to determine whether the requirements

of section 802(b)(3)(B) have been

satisfied. Section 802(b)(3)(A) of the act

requires that the agency publish a notice

in the Federal Register within 10 days

of the filing of an application for export

to facilitate public participation in its